These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 26108240)

  • 1. Bevacizumab treatment for vestibular schwannoma in a patient with neurofibromatosis type 2: hearing improvement and tumor shrinkage.
    Sponghini AP; Platini F; Rondonotti D; Soffietti R
    Tumori; 2015 Nov; 101(6):e167-70. PubMed ID: 26108240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.
    Hochart A; Gaillard V; Baroncini M; André N; Vannier JP; Vinchon M; Dubrulle F; Lejeune JP; Vincent C; Nève V; Sudour Bonnange H; Bonne NX; Leblond P
    J Neurooncol; 2015 Sep; 124(2):229-36. PubMed ID: 26022982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnostic image (252). A woman with complaints of tinnitus, hearing loss and headache].
    te Lintelo MP; Koehler PJ
    Ned Tijdschr Geneeskd; 2005 Nov; 149(46):2565. PubMed ID: 16320667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.
    Plotkin SR; Merker VL; Halpin C; Jennings D; McKenna MJ; Harris GJ; Barker FG
    Otol Neurotol; 2012 Aug; 33(6):1046-52. PubMed ID: 22805104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.
    Plotkin SR; Duda DG; Muzikansky A; Allen J; Blakeley J; Rosser T; Campian JL; Clapp DW; Fisher MJ; Tonsgard J; Ullrich N; Thomas C; Cutter G; Korf B; Packer R; Karajannis MA
    J Clin Oncol; 2019 Dec; 37(35):3446-3454. PubMed ID: 31626572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained response to bevacizumab in a patient with mosaic neurofibromatosis type 2 carrying the
    Basenach E; Förster A; Raab P; Alzein S; Schmidt G; Krauss JK; Schlegelberger B; Heidenreich F; Auber B; Hartmann C; Wiese B; Weber RG
    Clin Neuropathol; 2022; 41(4):162-167. PubMed ID: 35445657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.
    Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
    Eur Arch Otorhinolaryngol; 2015 Dec; 272(12):3627-33. PubMed ID: 25421643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.
    Blakeley JO; Ye X; Duda DG; Halpin CF; Bergner AL; Muzikansky A; Merker VL; Gerstner ER; Fayad LM; Ahlawat S; Jacobs MA; Jain RK; Zalewski C; Dombi E; Widemann BC; Plotkin SR
    J Clin Oncol; 2016 May; 34(14):1669-75. PubMed ID: 26976425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
    Plotkin SR; Stemmer-Rachamimov AO; Barker FG; Halpin C; Padera TP; Tyrrell A; Sorensen AG; Jain RK; di Tomaso E
    N Engl J Med; 2009 Jul; 361(4):358-67. PubMed ID: 19587327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients.
    Nunes FP; Merker VL; Jennings D; Caruso PA; di Tomaso E; Muzikansky A; Barker FG; Stemmer-Rachamimov A; Plotkin SR
    PLoS One; 2013; 8(3):e59941. PubMed ID: 23555840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 - a retrospective case series.
    Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
    Int J Neurosci; 2016 Nov; 126(11):1002-6. PubMed ID: 26365467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab for Hearing Preservation in Neurofibromatosis Type 2: Emphasis on Patient-Reported Outcomes and Toxicities.
    Sverak P; Adams ME; Haines SJ; Levine SC; Nascene D; Sommer K; Dusenbery K; Huang TC; Moertel C
    Otolaryngol Head Neck Surg; 2019 Mar; 160(3):526-532. PubMed ID: 30373466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2.
    Farschtschi S; Merker VL; Wolf D; Schuhmann M; Blakeley J; Plotkin SR; Hagel C; Mautner VF
    Acta Neurol Scand; 2016 Jun; 133(6):475-80. PubMed ID: 26369495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical treatment in neurofibromatosis type 2. Review of the literature and presentation of clinical reports.
    Goutagny S; Kalamarides M
    Neurochirurgie; 2018 Nov; 64(5):370-374. PubMed ID: 28162254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing the sensitivity of linear and volumetric MRI measurements to detect changes in the size of vestibular schwannomas in patients with neurofibromatosis type 2 on bevacizumab treatment.
    Morris KA; Parry A; Pretorius PM
    Br J Radiol; 2016 Sep; 89(1065):20160110. PubMed ID: 27452262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and meta-analysis of treatment outcomes.
    Lu VM; Ravindran K; Graffeo CS; Perry A; Van Gompel JJ; Daniels DJ; Link MJ
    J Neurooncol; 2019 Sep; 144(2):239-248. PubMed ID: 31254266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2.
    Farschtschi S; Kollmann P; Dalchow C; Stein A; Mautner VF
    Eur Arch Otorhinolaryngol; 2015 Dec; 272(12):3857-60. PubMed ID: 25794543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Audiologic presentation of vestibular schwannomas in neurofibromatosis type 2.
    Lalwani AK; Abaza MM; Makariou EV; Armstrong M
    Am J Otol; 1998 May; 19(3):352-7. PubMed ID: 9596188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of hearing in pediatric NF2.
    Shepard TH; Tucci DL; Grant GA; Kaylie DM
    Otol Neurotol; 2012 Aug; 33(6):1066-70. PubMed ID: 22710553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma.
    Plotkin SR; Allen J; Dhall G; Campian JL; Clapp DW; Fisher MJ; Jain RK; Tonsgard J; Ullrich NJ; Thomas C; Edwards LJ; Korf B; Packer R; Karajannis MA; Blakeley JO
    Neuro Oncol; 2023 Aug; 25(8):1498-1506. PubMed ID: 37010875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.